110 related articles for article (PubMed ID: 2943981)
1. Dopaminergic 2-aminotetralins: affinities for dopamine D2-receptors, molecular structures, and conformational preferences.
Johansson AM; Karlén A; Grol CJ; Sundell S; Kenne L; Hacksell U
Mol Pharmacol; 1986 Sep; 30(3):258-69. PubMed ID: 2943981
[TBL] [Abstract][Full Text] [Related]
2. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
Seiler MP; Markstein R
Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor agonists: an analysis of indirect models.
Johansson AM; Grol CJ; Karlén A; Hacksell U
Drug Des Discov; 1994 Feb; 11(2):159-74. PubMed ID: 7915550
[TBL] [Abstract][Full Text] [Related]
4. C1- and C3-methyl-substituted derivatives of 7-hydroxy-2-(di-n-propylamino)tetralin: activities at central dopamine receptors.
Johansson AM; Nilsson JL; Karlén A; Hacksell U; Sanchez D; Svensson K; Hjorth S; Carlsson A; Sundell S; Kenne L
J Med Chem; 1987 Oct; 30(10):1827-37. PubMed ID: 3656358
[TBL] [Abstract][Full Text] [Related]
5. Structural factors of importance for 5-hydroxytryptaminergic activity. Conformational preferences and electrostatic potentials of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and some related agents.
Arvidsson LE; Karlén A; Norinder U; Kenne L; Sundell S; Hacksell U
J Med Chem; 1988 Jan; 31(1):212-21. PubMed ID: 2961887
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacology of the enantiomers of cis-7-hydroxy-3-methyl-2-(dipropylamino)tetralin.
Johansson AM; Fredriksson K; Hacksell U; Grol CJ; Svensson K; Carlsson A; Sundell S
J Med Chem; 1990 Oct; 33(10):2925-9. PubMed ID: 2120444
[TBL] [Abstract][Full Text] [Related]
7. C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation.
Johansson AM; Nilsson JL; Karlén A; Hacksell U; Svensson K; Carlsson A; Kenne L; Sundell S
J Med Chem; 1987 Jul; 30(7):1135-44. PubMed ID: 3599021
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors.
Malmberg A; Nordvall G; Johansson AM; Mohell N; Hacksell U
Mol Pharmacol; 1994 Aug; 46(2):299-312. PubMed ID: 8078492
[TBL] [Abstract][Full Text] [Related]
9. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
[TBL] [Abstract][Full Text] [Related]
10. 5-Oxygenated N-alkyl- and N,N-Dialkyl-2-amino-1-methyltetralins. Effects of structure and stereochemistry on dopamine-D2-receptor affinity.
Grol CJ; Nordvall G; Johansson AM; Hacksell U
J Pharm Pharmacol; 1991 Jul; 43(7):481-5. PubMed ID: 1682460
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
Seeman P; Watanabe M; Grigoriadis D; Tedesco JL; George SR; Svensson U; Nilsson JL; Neumeyer JL
Mol Pharmacol; 1985 Nov; 28(5):391-9. PubMed ID: 2932631
[TBL] [Abstract][Full Text] [Related]
12. Conformational analysis of the dopamine-receptor agonist 5-hydroxy-2-(dipropylamino)tetralin and its C(2)-methyl-substituted derivative.
Karlén A; Johansson AM; Kenne L; Arvidsson LE; Hacksell U
J Med Chem; 1986 Jun; 29(6):917-24. PubMed ID: 3712382
[TBL] [Abstract][Full Text] [Related]
13. ACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro.
Florijn WJ; De Boer T; Tonnaer JA; Van Nispen JW; Versteeg DH
Eur J Pharmacol; 1991 May; 207(1):43-50. PubMed ID: 1680721
[TBL] [Abstract][Full Text] [Related]
14. 5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
Kuipers W; Kruse CG; van Wijngaarden I; Standaar PJ; Tulp MT; Veldman N; Spek AL; IJzerman AP
J Med Chem; 1997 Jan; 40(3):300-12. PubMed ID: 9022796
[TBL] [Abstract][Full Text] [Related]
15. A photoaffinity ligand for dopamine D2 receptors: azidoclebopride.
Niznik HB; Guan JH; Neumeyer JL; Seeman P
Mol Pharmacol; 1985 Feb; 27(2):193-9. PubMed ID: 3969068
[TBL] [Abstract][Full Text] [Related]
16. Perinatal asphyxia induces long-term changes in dopamine D1, D2, and D3 receptor binding in the rat brain.
Chen Y; Hillefors-Berglund M; Herrera-Marschitz M; Bjelke B; Gross J; Andersson K; von Euler G
Exp Neurol; 1997 Jul; 146(1):74-80. PubMed ID: 9225740
[TBL] [Abstract][Full Text] [Related]
17. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
Leff SE; Creese I
Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
[TBL] [Abstract][Full Text] [Related]
18. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
19. II. Pharmacological studies with derivatives of 2-aminotetralin, benzhydro[f]quinoline, benzhydro[g]quinoline, apomorphine and clonidine suggest a pharmacological dissimilarity between peripheral presynaptic dopamine receptors and alpha-2 adrenoceptors.
Maixner W; Flynn JR; Arnerić SP; Cannon JG; Long JP
J Pharmacol Exp Ther; 1983 Feb; 224(2):352-8. PubMed ID: 6296357
[TBL] [Abstract][Full Text] [Related]
20. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
